NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced that Brian Daniels, senior vice president, Global Development and Medical Affairs, will be retiring from the company, effective July 1, 2014.
"He has been a champion of the patients we serve, and I want to sincerely thank him for his loyalty and dedication to Bristol-Myers Squibb."
Dr. Daniels joined Bristol-Myers Squibb in 2000 and has held his current position as senior vice president, Global Development and Medical Affairs since 2008, leading the development of numerous innovative medicines such as Eliquis and Yervoy that address serious diseases and communicating the value of these medicines to society to ensure their safe and appropriate use.
"Brian has played a key leadership role in the success of the company's R&D organization and our ability to deliver innovative medicines to patients with serious diseases," said Francis Cuss, executive vice president and chief scientific officer, Bristol-Myers Squibb. "He has been a champion of the patients we serve, and I want to sincerely thank him for his loyalty and dedication to Bristol-Myers Squibb."
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.
Contacts
Bristol-Myers Squibb
Media:
Laura Hortas, 609-252-4587
[email protected]
or
Ken Dominski, 609-252-5251
[email protected]
or
Investors:
John Elicker, 609-252-4611
[email protected]
or
Ranya Dajani, 609-252-5330
[email protected]
or
Ryan Asay, 609-252-5020
[email protected]